Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A literature review of the pharmacokinetic profiles of 20 commonly prescribed antihypertensive medications for use in chemical adherence testing.

Journal of hypertension·2026
Same author

Investigating variations and early-life temporal changes in oxygen saturation indices in healthy moderate-late preterm and term infants: a cohort study.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Harnessing New Tools for Old Challenges: Optimising Neat Plasma Proteomics with Automation and Gas-Phase Fractionation.

ACS measurement science au·2026
Same author

Bridging the Gap: A Pre- and Post-evaluation of an Online Skin of Colour Dermatology Lecture Series for Medical Students.

Cureus·2025
Same author

Preharvest heat stress affects rocket salad leaf transcription and metabolism at harvest and after chilled postharvest storage.

Annals of botany·2025
Same author

A DESCRIPTION OF ADDISON'S DISEASE, AND ITS NEUROPSYCHIATRIC MANIFESTATIONS COMPARING THE DISEASE AS IT IS NOW TO THE DISEASE AS EXPERIENCED BY SAINT ELIZABETH OF THE TRINITY IN 1906.

Psychiatria Danubina·2025
Same journal

Transforming women's mental health with large language models: Opportunities and challenges in digital interventions.

Psychiatria Danubina·2026
Same journal

Impact of cognitive-behavioral therapy for early postpartum depression among primiparous women.

Psychiatria Danubina·2026
Same journal

The impact of housing conditions and nutritional quality on the psycho-emotional state of young internally displaced persons during the Russo-Ukrainian war: The role of secondary stressors.

Psychiatria Danubina·2026
Same journal

Beyond the pandemic: The case for removing obsolete COVID-19 signage in clinical spaces.

Psychiatria Danubina·2026
Same journal

Revamping mariner's mental health using quantum computing techniques.

Psychiatria Danubina·2026
Same journal

Integrating Pilates and myofunctional therapy for better sleep and psychosocial outcomes in obesity-associated obstructive sleep apnea.

Psychiatria Danubina·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Is oestrogen neuroprotective?

Mark Agius1, Helen Hockings, Charlotte Wilson

  • 1Academic Department of Psychiatry University of Cambridge, Bedfordshire and Luton Partnership Trust, UK. ma393@cam.ac.uk

Psychiatria Danubina
|October 1, 2009
PubMed
Summary
This summary is machine-generated.

Oestrogen may offer neuroprotection for individuals at ultra-high risk for psychosis. Research suggests it could enhance treatment efficacy, potentially by controlling apoptosis in early schizophrenia stages.

More Related Videos

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
06:51

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
09:07

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats

Published on: February 23, 2015

Related Experiment Videos

Last Updated: Jun 19, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
06:51

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
09:07

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats

Published on: February 23, 2015

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Neuroprotection is crucial for early psychosis intervention, particularly in individuals at ultra-high risk (UHR) for schizophrenia.
  • Apoptosis is accelerated in early schizophrenia, necessitating agents to manage this process.
  • Current antipsychotics have side effects, driving the need for alternative treatments for prodromal psychosis.

Purpose of the Study:

  • To explore the potential neuroprotective role of oestrogen in individuals at ultra-high risk for psychosis.
  • To investigate oestrogen's efficacy as an adjunct treatment for early psychosis, considering its effects on apoptosis.

Main Methods:

  • Review of existing studies on oestrogen's effects in schizophrenia treatment.
  • Analysis of the incidence of psychosis in relation to gender and menopausal status.
  • Examination of oestradiol's impact on antipsychotic efficacy in female patients.

Main Results:

  • Oestrogen has been suggested as a neuroprotective agent due to its potential to modulate apoptosis.
  • Studies indicate that adding oestradiol to antipsychotics enhances treatment efficacy in females with schizophrenia.
  • Oestrogen has not been previously investigated in ultra-high risk mental states due to potential side effect concerns.

Conclusions:

  • Oestrogen demonstrates potential neuroprotective properties relevant to early psychosis and schizophrenia.
  • Further research is warranted to evaluate oestrogen's safety and efficacy in ultra-high risk populations.
  • Oestrogen may represent a novel therapeutic avenue for managing prodromal psychosis and mitigating neurodegenerative processes.